Objective: To detect the relationship between molecular subtypes of breast cancer with expressions of androgen receptor, cytokeratin 5/6 (CK5/6)and Ki-67.
Introduction
Current parameters determining prognosis and adjuvant therapy protocol in breast cancer are patient's age, tumor size, histological grade, lymph node metastasis, status of estrogen receptor (ER) and/or progestereone receptor (PR) and of human epidermal growth factor receptor-2 (HER2) (1) . Molecularly distinct subtypes of breast cancer have been described by gene expression studies: hormone receptor-positive "luminal A"(LA) and "luminal B" (LB) cancers, hormone receptor-negative but HER2 overexpressing and/or amplified "HER2-enriched" cancers (HER2+), and triple negative cancers (TN) negative for both hormone receptors and HER2. Common immunohistochemical surrogates used by many investigators to discriminate those subtypes are ER, PR, HER2, Ki-67, cytokeratins (CK5/6) and epidermal growth factor receptor (EGFR) (2) . HER2 is negative in LA cancers and positive in LB, while both luminal subtypes express ER and/or PR. However, in St Galen Consensus 2013 some modifications were made in description of luminal cancers which is shown in Table 1 (3). HER2+ and TN cancers are hormone receptor-negative. TN tumors are known as basal-like when cytokeratins (CK5/6, CK17, CK14) or EGFR is expressed and as normal-like, when not (4) (5) .
Overall and recurrence-free survivals are better in LA subgroup (6) while hormone-negative HER tumors and basal-like tumors of TN group have poor prognosis (7) .
Androgens influence growth of normal and malignant breast cells. They inhibit basal and estradiole-stimulated proliferation by an androgen receptor (AR)-dependent mechanism (8) and also stimulate growth of breast cancer cells by aromatization to estrogens (9) . AR is expressed in 70-90% of invasive breast cancers, while frequency of expression of ER is 60-80% and of PR, 50-70% (10) . AR expression is usually associated with low tumor grade, small size, improved response to hormone therapy in hormone responsive cases and longer patient survival (9) (10) (11) . It has been reported that approximately 1/3 of ERnegative, high grade invasive ductal cancers and 75% of breast cancer metastases expressed AR (10, 11) . In TN cancers, AR expression has been reported with different incidences ranging from 13% to 45% (10) (11) (12) (13) .
In this study we aimed to detect the clinical significance of AR, CK5/6 and Ki-67 by correlating them with clinicopathological parameters in molecular subtypes of breast cancer.
Materials and Methods
Eighty-six invasive breast cancer cases operated between January 2007 and December 2010 were retrospectively evaluated. Patients treated for recurrent disease and those who received neoadjuvant therapy for locally advanced disease were excluded. Initial patient data were available from patient files as well as histopathological features of the disease. As the number of cases was low, molecular subtypes were determined as luminal A (ER and/or PR-positive and HER2-negative), luminal B (ER and/or PR-positive and HER2-positive), HER2 overexpressive (ER-negative, PR-negative and HER2-negative), and triple negative (ER-negative, PR-negative and HER2-negative Cases were labeled as positive for AR, ER and PR when 1% or more tumor cells expressed the marker ( Figure 1 and Figure 2 ). HER2 immunohistochemical staining was scored from 0 to +3 according to the guideline indicated for HercepTest TM (DAKO) (14) . It was considered positive when strong membranous staining (3+) was observed and negative, when the score was 0 or 1+. Fluorescence in situ hibridization test was used for those with 2+ staining. Ki-67 expression was quantified by visual grading. One way ANOVA test was used in the comparison of the groups, the variables did not indicate a normal distribution. Kruskal Wallis test was used in comparison of the groups and Chi-square and Fischer's exact test was used for evaluation of the qualitative data. Statistical significance level was established at P<0.05.
Results
Eighty-six invasive breast cancer cases of stages I, IIA and IIB were included. In all cases lumpectomy with clear margins was the operation performed. Axillary dissection was applied in 46 cases either as the primary procedure or after detection of metastasis in sentinel lymph node. All had radiotherapy but chemotherapy and hormone therapy were performed according to disease characteristics. Table 2 .
AR positivity was significantly more common in LA and LB groups than in HER2+ and TN (P=0.0001). CK5/6 was positive more commonly in HER2+ and TN groups (P=0.001). Higher Ki-67 value (in 74% of the cases) and high histological grade were detected more commonly in HER2+ group (P=0.04, P=0.034, respectively). Tumor type and rates of lymphovascular invasion and multifocal tumor were similar between groups. TN group had 2 deaths (P=0.04). Rate of local recurrence was not different between groups (P=0.383). Metastases were signifantly more common in HER2+ and TN groups (P=0.002). Comparision of the clinicopathological parameters together with AR, CK5/6 and Ki-67 status between 4 groups were demonstrated in Table 3 .
Two deaths were from TN group. Both were AR negative but survival in TN group was not significantly related to AR-negativity (χ²:0.49, P=0.486). CK5/6 was positive in one death and Ki-67 value was low in both. CK5/6-positivity and Ki-67 value had no association with survival in TN group (χ²:0.21, P=0.643 and χ²:1.24, P=0.266, respectively) (Table 4) .
AR was negative in all 6 patients with local recurrence. Only in LA group, association of AR negativity with development of local recurrence was statistically significant. Seven of the 9 cases with systemic metastasis were AR negative, which was not significant (Table 5) . CK 5/6 positivity was not significantly associated with development of local recurrence or systemic metastasis (Table 6 ). Both cases with local recurrence in HER2+ group had high Ki-67 value, which was significant. There was no significant relation between Ki-67 value and development of systemic metastasis in groups ( Table 7) .
Discussion and Conclusion
Clinical behavior of breast cancer changes with its molecular subtype. Analysis of 12 studies evaluating data from a total of 10,105 breast cancer cases revealed that 78% of the total was luminal tumors and 92% of the luminal cases were LA (16) . In different studies approximately 15% of the cases were HER2+ and another 15%, TN (17) . Special importance has been given to HER2+ and TN subgroups as both have poor prognosis and TN cancers have no specific targeted therapy (1).
In our study, molecular subtypes were LA in 47.7%, LB in 16.27%, HER2+ in 16.27% and TN in 19.76%. HER2+ group had high histological grade and high Ki-67 value more commonly than other subgroups. Also other characteristics demonstrating poor prognosis were observed significantly more in HER2+ and TN subgroups, such as, CK5/6 expression, AR negativity and development of systemic metastases, in correlation with other previous studies. Also both deaths were TN.
Mortality in subgroups of breast cancer was reported to be time-dependent (16) . Within the first years after diagnosis of cancer, it was reported that both HER2+ and TN subgroups had more mortality than LA tumors. It was also demonstrated that LB tumors had poorer prognosis than both HER2+ and LA tumors, and that within TN group basal-like tumors had worse prognosis than non-basal tumors. However, the differences in mortality rates between subgroups reversed after 5-10 years of diagnosis (15, 18) . Effects of ER, PR, HER2 and CK5/6 on prognosis were also reported to change with time (7, 16, 19) . Thus research on prognostic differences among molecular subtypes requires large groups with prolonged follow-ups.
Short follow-up period in our study limited the ability to compare survival between the subgroups. The only 2 deaths observed were from TN subgroup. Deaths were recorded at the 24 th and 28 th months of initial diagnosis supporting the previous studies emphasizing the risk within the first years in HER2+ and TN subgroups.
The biomarker used in discrimination of basal tumors, CK5/6, is associated with aggressive behavior and increased risk for systemic metastases (20, 21). Basal-like tumors formed approximately 58% of the TN subgroup and had poorer prognosis. However, basal markers did not affect the prognosis significantly within HER2+ subgroup (16) . In our study as the number of cases was low, we did not have the chance to divide TN subgroup as basal and non-basal tumors. CK5/6 expression was more common in HER2+ and TN subgroups, but development of local recurrence or systemic metastasis was not significantly affected by its expression which might be due to short follow-up period.
Ki-67 is a cell proliferation marker in breast cancer and also a biomarker used in identification of LB tumors (1). It has been reported that high Ki-67 expression is significantly associated with breast cancer recurrence and death (22, 23) . After neoadjuvant endocrine therapy, changes in Ki-67 expression may help predict long-term outcome (24) .
In our study expression of high Ki-67 value was observed significantly more commonly in HER2+ subgroup (71% AR expression is common in well differentiated breast cancers which are positive for ER and PR (10, 13, 24) . Loss of AR expression is usually associated with early onset, high grade tumors negative for ER, PR and HER2 (12) . Although the lowest AR expression was observed in TN cancers (24) , up to 30% of them were positive for AR (10, 13, 25) . That's why it was suggested that AR could be a potential target in management of AR-positive TN breast cancers in future. In our study AR was more commonly expressed in LA cancers (90%) and rate of expression in TN subgroup was 18%.
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J Breast Health 2014; 10: 201-8 Several studies suggested that AR expression can have prognostic role, especially in ER-positive cancers (12, 26) . It was reported that higher expression of AR was associated with lower rate of local recurrence and death (27) . Thus, AR expression in hormone responsive cases has recently been suggested as an independent prognostic factor for better disease free survival like ER status (28) . In our study, AR was also positive in 78% of all hormone responsive cases. Observation of AR negativity was noteworthy in all 6 patients with local recurrence, 7 of the 9 cases with systemic metastasis and both dead cases. In LA subgroup, AR negativity in presence of ER/PR-positivity was significantly related to development of local recurrence. Low number of patients with short follow-up period in the study might be the reason for the insignificant results obtained.
The fact that AR is also detected in 9% to 56% of ER/PR-negative breast cancers made AR expression important (5, 10, 25, 29) . ARpositivity was reported to be a significant prognostic factor for disease free survival also in cases negative for ER (11) . Many investigators suggested AR as a potential therapeutic target in AR-positive, ER-negative cancers (30) . ER-negative cases, when AR is also negative, have an aggressive course with less clinical response to hormonal therapy (31) . In our study AR expression was detected in 20% of the cases negative for both ER and PR. Four of the 6 local recurrences, 7 of the 9 systemic metastases and both of the deaths were also negative for ER and PR.
Our study supported previous studies that molecular subtypes of breast cancer are prognostic and predictive. AR was expressed more commonly in luminal cancers and AR negativity was associated with development of local recurrence in luminal A cancers. However to determine potential role of androgen receptor in followup and treatment of triple negative breast cancers, larger studies with longer follow-ups are required. 
